Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response

• मुख्य लेखकों: Jian Lin (लेखक), Francois Gaudreault (लेखक), Nathaniel Johnson (लेखक), Zhiwu Lin (लेखक), Parya Nouri (लेखक), Theunis C. Goosen (लेखक), Aarti Sawant‐Basak (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2022-09-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract PF‐05251749 is a dual inhibitor of casein kinase 1 δ/ε under clinical development to treat disruption of circadian rhythm in Alzheimer's and Parkinson's diseases. In vitro, PF‐05251749 (0.3-100 μM) induced CYP3A in cryopreserved human hepatocytes, demonstrating non‐saturable, dose...